Study of daratumumab and lenalidomide for resistant multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, daratumumab and lenalidomide, for patients with multiple myeloma that has not responded to previous treatments. It aims to see if this regimen can help when other therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back or did not respond to treatment.
- You have had a previous treatment with a type of drug called an anti-CD38 antibody (like daratumumab) combined with an IMiD (like lenalidomide).
- You are 18 years or older.
- You are willing to understand and sign a consent form and allow your medical data to be reviewed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial studies elranatamab (alone and combined with daratumumab) in people with multiple myeloma who have already received other treatments, including lenalidomide. It aims to see how well these medicines control the cancer and what side effects people experience.
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests a new combination of two drugs, ramantamig and daratumumab, against other standard treatments for people newly diagnosed with multiple myeloma who are not planning to have a stem cell transplant. The goal is to see if this combination works better at controlling the cancer.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.